Abstract:Sebawe Syaj, Anwaar Saeed Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Correspondence: Anwaar Saeed, Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Email Colorectal cancer (CRC) is a prevalent and deadly cancer, with metastatic CRC (mCRC) often leading to poor outcomes despite advancements in screening and chemotherapy. Anti-angiogenic agents targeting vascular endothelial growth factor (VEGF) pathways have become essential in mCRC treatment. Bevacizumab, a VEGF inhibitor, was the first agent used in this context. However, drug resistance prompted the development of more selective inhibitors, such as fruquintinib, a tyrosine kinase inhibitor (TKI) that targets VEGFR-1, − 2, and − 3. Fruquintinib has shown promise in clinical trials, particularly for third-line mCRC treatment. The Phase III FRESCO trial in China demonstrated its efficacy, significantly improving overall survival (OS) and progression-free survival (PFS) compared to placebo, with manageable safety concerns like hypertension and hand-foot skin reactions. The FRESCO-2 trial extended these findings to European and North American populations, leading to a recent FDA approval for previously treated mCRC patients. The pharmacodynamic profile of fruquintinib includes potent inhibition of VEGFR, angiogenesis, and lymphangiogenesis. It has shown synergistic effects when combined with other treatments like chemotherapy and immune checkpoint inhibitors (ICIs). Current research focuses on exploring fruquintinib's combination with ICIs, such as PD-1 inhibitors, to enhance treatment efficacy, especially in microsatellite stable (MSS) CRC. Ongoing trials are investigating Fruquintinib's potential in combination with other therapies and its use in earlier lines of treatment. While promising, further studies are required to optimize its place in therapy and identify predictive biomarkers for better patient selection. Keywords: fruquintinib, angiogenesis, VEGF inhibitor, refractory mCRC, third-line Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death, affecting almost 2 million people per annum. 1 Around half of CRC patients develop distant metastasis and the overall survival rate is 15% at 5 years. 2,3 Screening colonoscopy and stool occult blood testing have decreased mortality rates. However, treatment development is still suboptimal. Currently, the mainstay therapies are chemotherapy with agents like fluoropyrimidines, oxaliplatin and irinotecan. 4 Combining chemotherapy with monoclonal antibodies is the standard of care for microsatellite stable metastatic CRC (mCRC). These antibodies are drugs directed against either the epidermal growth factor receptor (EGFR) or the vascular endothelial growth factor (VEGF) based on the patient's molecular profile and the primary tumor location. 2,5 Unfortunately, most patients with mCRC eventually become nonresponsive, insensitive, or intolerant to these treatments, and the options are still limited for CRC patients who progress after 2 lines of treatment. 6 In this article, we will review the design, development, and potential place of fruquintinib, a new oral VEGFR inhibitor for third- or later-line use in mCRC patients. Angiogenesis is the generation of new blood vessels from existing vasculature, it plays a role in embryonic development and tumorigenesis. 7,8 It is a main element in cell proliferation, vascular remodeling, and cancer metastasis. The VEGF is a crucial pathway of angiogenesis. 9 The blockage of angiogenesis has become an effective treatment for multiple cancer types. 10 Anti-angiogenic agents function by blocking the ligand (VEGF inhibitors) or the receptor (VEGFR inhibitors). Bevacizumab is a humanized monoclonal antibody against the VEGF-A ligand, it is the first drug that achieved approval in combination with chemotherapy for mCRC. 8 It functions by binding to VEGF, thus, preventing it from binding to its receptor. Therefore, jeopardizing the signal transduction pathway that leads to angiogenesis, proliferation, and migration of cancer cells. 11 Later in a pivotal trial, Bevacizumab was discovered to work in second-line settings or for patients with disease progression. 12 Blocking VEGF-A leads to an increase in other components in the VEGF axis such as VEGF-C, VEGF-D, and the platelet-derived growth factor (PDGF), eventually leading to resistance to bevacizumab treatment. This was confirmed by Hayashi et al during their evaluation of serum concentrations of biomarkers before and after treatment with a combination of bevacizumab and the FOLFIRI regimen (folinic acid, fluorouracil, and -Abstract Truncated-

Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

Profile of Fruquintinib in the Management of Advanced Refractory Metastatic Colorectal Cancer: Design, Development and Potential Place in Therapy

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Efficacy and Safety of Fruquintinib Plus Investigator's Choice of Chemotherapy As Second-Line Therapy in Metastatic Colorectal Cancer: Updated Results of a Multicenter, Single-Arm, Phase 2 Trial.

OA11.03 A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.

Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer.

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

Fruquintinib Effectively Controlled the Advanced Small Bowel Adenocarcinoma Progressed after Multiple Lines of Palliative Treatment: a Case Report and Literature Review

A Phase 1b Study of VEGFR Inhibitor Fruquintinib in Patients with Pretreated Advanced Colorectal Cancer.

Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study

Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors

JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (pts) with Metastatic Colorectal Cancer (mcrc): Profile-Matched Data from FRESCO and FRESCO-2

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Phase I Study of Safety and Pharmacokinetics of Fruquintinib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases in Patients with Advanced Solid Tumors.

Preliminary efficacy and safety of fruquintinib as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, randomized, open-label clinical trial (the FRONT study).

Clinical research progress of fruquintinib in the treatment of malignant tumors

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.

Synergistic Effects of Fruquintinib Combined with Immune Checkpoint Inhibitors on Metastatic Colorectal Cancer